Hematopoietic stem cell transplantation protects mice from lethal stroke.

Area of Science:

• Neuroscience
• Regenerative Medicine
• Hematology

Background:

• Stroke is a leading cause of death and disability in the US.
• Current treatments are limited; ideal therapies aim to reduce cell death and promote brain regeneration.
• Investigating novel therapeutic strategies is crucial for improving stroke outcomes.

Purpose of the Study:

• To evaluate the efficacy of hematopoietic stem cell transplantation in a mouse model of stroke.
• To determine the optimal timing and cell type for bone marrow cell transplantation post-stroke.
• To assess the impact of this therapy on survival and neurological recovery.

Main Methods:

• A middle cerebral artery occlusion (MCAO) mouse model was used to induce stroke.
• Bone marrow cells, specifically Sca1+ cells enriched in hematopoietic stem cells, were transplanted intravenously.
• Optimal transplantation timing (days 1 and 2 post-surgery) and dose-response effects were investigated.

Main Results:

• Intravenous injection of Sca1+ bone marrow cells significantly improved survival rates (99% mortality without treatment vs. survival in treated mice).
• A dose-response effect was observed, with higher doses of Sca1+ cells correlating with better survival.
• Surviving mice showed no signs of paralysis or weakness, indicating remarkable neurological recovery.

Conclusions:

• Hematopoietic stem cell-rich Sca1+ bone marrow cell transplantation is a protective strategy following stroke.
• This therapy effectively alleviates neurological morbidity in surviving stroke-affected mice.
• The findings suggest a promising therapeutic potential for stem cell-based interventions in stroke recovery.